MiNK Therapeutics, Inc. (INKT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 11.62 |
| Open | 11.76 |
| Day High | 12.2 |
| Day Low | 11.76 |
| 52-Week High | 16.98 |
| 52-Week Low | 8.48 |
| Volume | 11,763 |
| Average Volume | 22,156 |
| Market Cap | 60.78M |
| PE | -5.17 |
| EPS | -2.36 |
| Moving Average 50 Days | 11.31 |
| Moving Average 200 Days | 11.45 |
| Change | 0.58 |
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
GlobeNewswire Inc.
Mar 10, 2026 9:30 AM GMT
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation NEW YORK, March 10, 2026 (GLOBE
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
GlobeNewswire Inc.
Feb 04, 2026 2:30 AM GMT
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXING
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
GlobeNewswire Inc.
Jan 08, 2026 5:00 PM GMT
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk